China-based HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) dosed the first patient in a global Phase I trial of HMPL-A830, the KRAS-EGFR antibody-targeted therapy conjugate licensed to GSK earlier this month in a deal worth up to USD 1.295 billion.
The Phase Ia dose-escalation study is evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors, with the first patient dosed in China on September 24, 2026. The Phase Ia dose-escalation portion will assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity before planned dose expansion in selected tumors.
HMPL-A830 combines a KRAS small-molecule inhibitor payload with an anti-EGFR antibody, with HUTCHMED describing it as a first-in-class approach designed to deliver KRAS inhibition selectively to EGFR-expressing tumors while simultaneously blocking EGFR signaling.
GSK secured worldwide rights to HMPL-A830 outside mainland China, Hong Kong, Macau, and Taiwan on September 3, paying HUTCHMED USD 110 million upfront with up to USD 1.185 billion in additional milestones plus royalties. HUTCHMED is responsible for the global Phase I program, after which GSK will lead further development in its territories. Initial development is expected to focus on colorectal, pancreatic, and lung cancers.